ChemicalBook >> journal list >> Scientific Reports >>article
Scientific Reports

Scientific Reports

IF: 3.8
Download PDF

Characterization of a pleomorphic rhabdomyosarcoma cell line

Published:23 January 2025 DOI: 10.1038/s41598-025-87027-2 PMID: 39843506
Sandra Stickler, Clemens Lang, Maximilian Rieche, Marie-Therese Eggerstorfer, Martin Hohenegger, Maximilian Hochmair, Gerhard Hamilton

Abstract

Pleomorphic rhabdomyosarcoma (PRMS) is an extremely rare soft tissue tumor with dismal prognosis that has a higher incidence in adults compared to the other RMS subtypes. The unique PRMS cell line BH1522 was established from a pleural effusion of a lung metastasis and the characteristics of this cell line were compared to two embryonal type RMS (ERMS) cell lines. The affected patient had been treated by surgery, several cycles of chemotherapy and thoracoscopy of the lung metastases. Chemosensitivity of the PRMS cell lines was checked using cytotoxicity assays and oncogene-related and phosphoproteins by Western blot arrays. The BH1522 cell line proved to be chemosensitive to conventional chemotherapeutics and the Son of Sevenless 1 homolog (SOS1) inhibitor BAY-293 that inhibited proliferation and suppressed MYC activity. Results of the novel functional BH1522 tests corroborate published tumor sequencing data that demonstrated alterations in receptor tyrosine kinase/MAPK, PI3K/AKT and mutated p53 as suspected drivers of malignant growth.

Substances (8)

Materials
Procduct Name CAS Molecular Formula Supplier Price
ARV-771 1949837-12-0 C49H60ClN9O7S2 116 suppliers $57.00-$4173.50
ARV-771 1949837-12-0 C49H60ClN9O7S2 116 suppliers $57.00-$4173.50
ARV-771 1949837-12-0 C49H60ClN9O7S2 116 suppliers $57.00-$4173.50
ARV-771 1949837-12-0 C49H60ClN9O7S2 116 suppliers $57.00-$4173.50
BAY-293 2244904-70-7 C25H28N4O2S 80 suppliers Inquiry
BAY-293 2244904-70-7 C25H28N4O2S 80 suppliers Inquiry
BAY-293 2244904-70-7 C25H28N4O2S 80 suppliers Inquiry
BAY-293 2244904-70-7 C25H28N4O2S 80 suppliers Inquiry

Similar articles

IF:0.8

Establishment of a CPAMD8-GFP reporter human embryonic stem cell line, IBBDe001-B, using CRISPR/Cas9 editing

Stem cell research Shun Zhang, Jiahang Li,etc Published: 22 November 2024
IF:29.7

Brigatinib Outperforms Crizotinib as First-Line Therapy.

Cancer discovery Published: 1 February 2020
IF:0

Isolation and Characterization of a Sulfanilic Acid Degrading Bacterial Strain

Applied Mechanics and Materials Yan Yang, Chu Wu,etc Published: 1 December 2011